# Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis

**Authors:** Shuya Hashimoto, Toyoshi Yanagihara, Natsumi Kushima, Rei Sanai, Takato Ikeda, Naoki Hamada, Masaki Fujita

PMC · DOI: 10.7759/cureus.81083 · Cureus · 2025-03-24

## TL;DR

This case study shows that hypertonic glucose pleurodesis can effectively treat refractory hepatic hydrothorax with fewer complications compared to conventional methods.

## Contribution

The study introduces hypertonic glucose as a safer alternative for pleurodesis in patients with advanced liver cirrhosis.

## Key findings

- Hypertonic glucose pleurodesis resolved pleural effusion without significant renal or hepatic complications.
- Pleural adhesion was confirmed two months after treatment, indicating long-term effectiveness.
- The approach may be suitable for patients who cannot undergo transjugular intrahepatic portosystemic shunt or liver transplantation.

## Abstract

Hepatic hydrothorax presents a significant challenge in advanced liver cirrhosis management, especially when conventional therapies fail. We report a case of a 66-year-old male with hepatitis C-related cirrhosis and advanced hepatocellular carcinoma who developed refractory left-sided hepatic hydrothorax despite maximal diuretic therapy. After failed talc pleurodesis, we employed an alternative approach using 50% glucose solution as a sclerosing agent. Following three sessions of hypertonic glucose pleurodesis, the patient achieved sustained resolution of pleural effusion with only minor, transient complications including hypotension and mild inflammatory response. Notably, he did not develop significant renal dysfunction or hepatic decompensation, complications commonly associated with conventional sclerosing agents in liver cirrhosis. Two-month follow-up imaging confirmed persistent pleural adhesion. This case highlights hypertonic glucose pleurodesis as a potentially safer alternative for managing refractory hepatic hydrothorax, particularly in patients unsuitable for transjugular intrahepatic portosystemic shunt or liver transplantation. However, further research is needed to establish optimal protocols, patient selection criteria, and long-term outcomes of this approach.

## Linked entities

- **Chemicals:** talc (PubChem CID 165411828)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Diseases:** liver cirrhosis (MESH:D008103), hepatocellular carcinoma (MESH:D006528), hypotension (MESH:D007022), renal dysfunction (MESH:D007674), pleural adhesion (MESH:D010995), cirrhosis (MESH:D005355), hepatic decompensation (MESH:D006333), hepatitis C (MESH:D019698), pleural effusion (MESH:D010996), inflammatory (MESH:D007249), Hepatic Hydrothorax (MESH:D006876)
- **Chemicals:** Glucose (MESH:D005947), talc (MESH:D013627)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12017293/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12017293/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12017293/full.md

---
Source: https://tomesphere.com/paper/PMC12017293